Your browser doesn't support javascript.
loading
Health economic impact of moderate-to-severe chronic pain associated with osteoarthritis in England: a retrospective analysis of linked primary and secondary care data.
Coates, Greg; Clewes, Peter; Lohan, Christoph; Stevenson, Hannah; Wood, Robert; Tritton, Theo; Knaggs, Roger; Dickson, Alastair J; Walsh, David.
Afiliação
  • Coates G; Pfizer Ltd, Tadworth, UK.
  • Clewes P; Pfizer Ltd, Tadworth, UK.
  • Lohan C; Pfizer Australia Pty Ltd, Sydney, New South Wales, Australia.
  • Stevenson H; Pfizer Ltd, Tadworth, UK.
  • Wood R; Adelphi Real World, Bollington, UK robert.wood@adelphigroup.com.
  • Tritton T; Adelphi Real World, Bollington, UK.
  • Knaggs R; Pain Centre Versus Arthritis and NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, UK.
  • Dickson AJ; Primary Care Rheumatology & Musculoskeletal Medicine Society, York, UK.
  • Walsh D; The North of England Low Back Pain Pathway, NIHR Applied Research Collaboration North East and North Cumbria, St Nicholas' Hospital, Newcastle Upon Tyne, UK.
BMJ Open ; 13(7): e067545, 2023 07 12.
Article em En | MEDLINE | ID: mdl-37438077
ABSTRACT

OBJECTIVE:

Despite the prevalence of osteoarthritis (OA) in England, few studies have examined the health economic impact of chronic pain associated with OA. The aim of this study was to compare outcomes in patients with moderate-to-severe chronic pain associated with OA and matched controls without known OA.

DESIGN:

Retrospective, longitudinal, observational cohort study.

SETTING:

Electronic records extracted from the Clinical Practice Research Datalink GOLD primary care database linked to Hospital Episode Statistics (HES) data set.

PARTICIPANTS:

Patients (cases; n=5931) ≥18 years and with existing diagnosis of OA and moderate-to-severe pain associated with their OA, and controls matched on age, sex, comorbidity burden, general practitioner (GP) practice and availability of HES data.

INTERVENTIONS:

None. PRIMARY AND SECONDARY OUTCOME

MEASURES:

Total healthcare resource use (HCRU) and direct healthcare costs during 0-6, 0-12, 0-24 and 0-36 months of follow-up. Secondary outcomes measures included pharmacological management and time to total joint replacement.

RESULTS:

Patients with moderate-to-severe chronic pain associated with OA used significantly more healthcare services versus matched controls, reflected by higher HCRU and significantly higher direct costs. During the first 12 months' follow-up, cases had significantly more GP consultations, outpatient attendances, emergency department visits and inpatient stays than matched controls (all p<0.0001). Total mean costs incurred by cases during 0-12 months' follow-up were five times higher in cases versus controls (mean (SD) £4199 (£3966) vs £781 (£2073), respectively). Extensive cycling through pharmacological therapies was observed; among cases, 2040 (34.4%), 1340 (22.6%), 841 (14.2%), 459 (7.7%) and 706 (11.9%) received 1-5, 6-10, 11-15, 16-20 and >20 lines of therapy, respectively.

CONCLUSIONS:

This wide-ranging, longitudinal, observational study of real-world primary and secondary care data demonstrates the impact of moderate-to-severe chronic pain associated with OA in patients compared with matched controls. Further studies are required to fully quantify the health economic burden of moderate-to-severe pain associated with OA.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoartrite / Dor Crônica Tipo de estudo: Etiology_studies / Health_economic_evaluation / Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoartrite / Dor Crônica Tipo de estudo: Etiology_studies / Health_economic_evaluation / Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article